





MeRes100™ - BRS Enhanced Radiopacity




MeRes100™ couplets of tri-axial RO markers on both ends of the scaffold, gives a sense of virtual tubing and high operator comfort.

Distance from edge of Balloon RO marker (both proximal & distal) to edge of Scaffold RO = 1.3 mm

MeRes100™ - BRS Best-in-Class Strut Thickness



MeRes100™ is a 100 µm strut thickness scaffold with a propensity to minimize vascular injury & ensure early endothelialization.




Unique manufacturing process, novel hybrid design concept incorporating strut width variability allows for best-in-class, **DES-like strut thickness** in MeRes100™.

MeRes100™ - BRS Best-in-Class Crossing Profile



Average profile of 1.2 mm for Ø 3.00 mm



Unique crimping process, novel hybrid design concept incorporating low strut thickness allows for best-in-class, **DES-like crossing profile** in MeRes100™.

1. OCT Image courtesy of Dr. Daniel Chamis, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil. 2. Data on file at Meril Life Sciences Pvt. Ltd.

MeRes100™ - BRS TECHNICAL SPECIFICATIONS

SCAFFOLD BACKBONE
 Scaffold Material : BioResorbable PLLA (Poly L-lactide)
 Scaffold Strut Thickness : 100 µm
 Scaffold Diameters : 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 4.00 mm
 Scaffold Lengths : 13, 16, 19, 24, 29, 32, 37, 40 mm

SCAFFOLD RO MARKERS
 Tri-axial RO Markers : Platinum (Couplets of tri-axial RO markers on both ends, 120° apart from each other)

TOP COAT-DRUG+POLYMER
 Drug : Sirolimus
 Equivalent Drug Dose : 1.25 µg / mm²
 Polymer : BioResorbable PDLLA (Poly D, L-lactide)

DELIVERY SYSTEM
 Delivery System : Rapid Exchange
 Nominal Pressure (NP) : 9 atm
 Rated Burst Pressure (RBP) : 16 atm
 Balloon Overhang : < 0.5 mm
 Shaft Outer Diameter : Proximal 1.95 F / Distal 2.7 F
 Radiopaque Markers : 2 - Platinum / Iridium
 Usable Catheter Length : 140 cm
 Guide Catheter Compatibility : 6 F (Min. I.D 0.070" / 1.8 mm)
 Max. Guidewire : 0.014" (0.36 mm)

MeRes100™ - BRS ORDERING INFORMATION

Dia / Lengths	13 mm	16 mm	19 mm	24 mm
2.25 mm	MRS22513	MRS22516	MRS22519	MRS22524
2.50 mm	MRS25013	MRS25016	MRS25019	MRS25024
2.75 mm	MRS27513	MRS27516	MRS27519	MRS27524
3.00 mm	MRS30013	MRS30016	MRS30019	MRS30024
3.25 mm	MRS32513	MRS32516	MRS32519	MRS32524
3.50 mm	MRS35013	MRS35016	MRS35019	MRS35024
4.00 mm	MRS40013	MRS40016	MRS40019	MRS40024

Dia / Lengths	29 mm	32 mm	37 mm	40 mm
2.25 mm	MRS22529	MRS22532	MRS22537	MRS22537
2.50 mm	MRS25029	MRS25032	MRS25037	MRS25040
2.75 mm	MRS27529	MRS27532	MRS27537	MRS27540
3.00 mm	MRS30029	MRS30032	MRS30037	MRS30040
3.25 mm	MRS32529	MRS32532	MRS32537	MRS32540
3.50 mm	MRS35029	MRS35032	MRS35037	MRS35040
4.00 mm	MRS40029	MRS40032	MRS40037	MRS40040

MeRes100 is not approved by USFDA and not available for sale in USA.
 Information for the use only in countries with applicable health authority product registrations.
 Absorb is a product of Abbott Laboratories, Resolute Integrity is a product of Medtronic, DESolve and DESolve CX is a product of Elixir Medical, ReZolve and Fantom is a product of REVA Medical, Magmaris is a product of Biotronik AG



More to Life

Meril Life Sciences Pvt. Ltd.
 M1-M2, Meril Park,
 Survey No 135/2/B & 174/2,
 Muktanand Marg, Chala,
 Vapi - 396 191, Gujarat, India.
 T +91 260 305 2100
 F +91 260 305 2125

Meril, Inc.
 2436 Emrick Boulevard,
 Bethlehem, PA 18020
 T +1 609 951 2287
 F +1 609 520 1702

Meril South America
 Doc Med LTDA
 Al. dos Tupiniquins,
 1079 - Cep: 04077-003 - Moema,
 Sao Paulo, Brazil.
 T +55 11 3624 5935
 F +55 11 3624 5936

Meril GmbH.
 Bornheimer Strasse 135-137,
 D-53119 Bonn,
 Germany.
 T +49 228 7100 4000
 F +49 228 7100 4001

Meril Tibbi Cihazlar
 Imalat Ve Ticaret A. S.
 6. Mimar sinan Mah.,
 Çavusbasi Cad. Özde Sok.
 Aydın Eksi Is Merkezi Kat:1
 Çekmekoy/Istanbul, Turkey.
 T +90 53 2272 5172

Meril China Co. Ltd.
 2301B, 23F, Lixin Plaza,
 no 90 South Hubin Road,
 Xiamen, China
 T 0086-592-5368505
 F 0086-592-5368519

Meril SA Pty. Ltd.
 Unit 7, Stoney Ridge Office Park,
 Corner Witkoppen Road And Waterford,
 Paulshof - Johannesburg, Gauteng - 2191,
 South Africa
 T +27 11 465-2049
 F +27 86 471 7941

Meril Medical LLC.
 Nauchnyi Proezd 19,
 Moscow, Russia - 117 246.
 Office - +7 495 772 7643

EU representative.
 Obelis S.A.
 Bd. General Wahis 53,
 1030, Brussels, Belgium.
 T +32 2 732 5954
 F +32 2 732 6003
 E mail@obelis.net

www.merilife.com

For the use of a Registered Medical Practitioner of Hospital or Laboratory only

MeRes100™
 Sirolimus Eluting BioResorbable Vascular Scaffold System
 Simply Sublime.




Cardiovascular



MeRes100™

Sirolimus Eluting BioResorbable Vascular Scaffold System
Simply Sublime.

Next Generation BioResorbable Scaffold.



Size Matrix
Diameters: 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 4.00 mm
Lengths: 13, 16, 19, 24, 29, 32, 37, 40 mm




MeRes-1 FiM Study: Safety and Efficacy of BRS in 108 Patients with Single, De-novo Coronary Lesions (in up to 2 vessels)

2-Year Follow-up

0% Scaffold Thrombosis
Cardiac Death
Myocardial Infarction

Late Lumen Loss



Clinical follow-up results

MACE, n(%)	Discharge N=108 (100%)	1-month N=108 (100%)	6-month N=108 (100%)	1-year* N=107 (99%)	2-year* N=107 (99%)
MACE	0 (0%)	0 (0%)	0 (0%)	1 (0.93%)	2 (1.87%)
Cardiac death	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Myocardial infarction [®]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ischemia-driven TLR	0 (0%)	0 (0%)	0 (0%)	1 (0.93%)	2 (1.87%)
Ischemia-driven TVR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3(2.80%)
Scaffold thrombosis [§]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

@Myocardial Infarction defined as per WHO criteria; SARC defined criteria.

Paired assessment of OCT

N=9	Post-Procedure	6-month	2-years
Mean abluminal scaffold area(mm ²)	8.06	8.64	8.39
Mean strut core area (mm ²)	0.14	0.11	0.06
% Covered struts	-	98.99%	99.24%


OCT analysis done by Cardialysis, Rotterdam, The Netherlands

MeRes100™ BRS Implantation


Proximal LAD sub-occlusive stenosis and clinical outcome.

53 Years | Male | Diabetic | Hypertensive | No family history | Non-smoker | Stable angina

Diagnostic Angio




MeRes100 3.50 x 19 mm




Final Result




Baseline OCT



6-Months f/up



6-Months OCT f/up



Data on file at Meril Life Sciences, Pvt. Ltd.

* Seth A et al. First-in-human evaluation of novel poly-L-lactide based sirolimus-eluting Bioresorbable Vascular Scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial 2017:415-23.